Document is current
Any future updates will be listed below
-
Authors
Reho, Paolo
Ray, Anindita
Kaivola, Karri
,
Vardarajan, Badri N.
Wu, Haotian
Scholz, Sonja W.
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (ZIANS003154)
National Institute on Aging (P30AG07231)
National Institutes of Health (U01 NS100620)
- License Information
-
More Information
Article History
Received: 20 September 2024
Revised: 7 August 2025
Accepted: 8 August 2025
First Online: 29 August 2025
Declarations
:
: S.W.S. serves on the scientific advisory board of the Lewy Body Dementia Association, Mission MSA, and the GBA1 Canada initiative. S.W.S. receives research support from Cerevel Therapeutics. All other authors have no competing interests to declare. Conflict of interest statement for consortium members: Zbigniew K. Wszolek, MD is partially supported by the NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), the Haworth Family Professorship in Neurodegenerative Diseases fund, the gifts from The Albertson Parkinson's Research Foundation, PPND Family Foundation, and Margaret N. and John Wilchek Family. He serves as PI or Co-PI on Biohaven Pharmaceuticals, Inc. (BHV4157-206), Vigil Neuroscience, Inc. (VGL101-01.002, VGL101-01.201, Csf1r biomarker and repository project, and ultra-high field MRI in the diagnosis and management of CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia), ONO-2808–03, and Amylyx AMX0035-009 projects/grants. He serves as Co-PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc., and as a consultant for Eli Lilly & Company and for NovoGlia, Inc.
